New Zealand approved Tune Therapeutics' TUNE-401, an epigenetic editing therapy for chronic hepatitis B, for human trials. Led by Ed Gane at Auckland City Hospital, it's the second HBV genome-altering therapy to enter trials after Precision Bioscienc